Patient and Caregiver Attitudes and Beliefs Regarding Prescription of Intranasal Naloxone Spray for Opioid Overdose

M.D. Anderson Cancer Center

Status

Active, not recruiting

Conditions

Patient

Caregiver

Treatments

Other: Survey Administration

Study type

Observational

Funder types

Other

NIH

Identifiers

NCT04129138

NCI-2019-06740 (Registry Identifier)

2019-0330 (Other Identifier)

Details and patient eligibility

About

This trial studies the attitudes and beliefs of high risk patients and caregivers regarding the prescription of intranasal naloxone spray for opioid overdose. Knowledge regarding high risk patients' and caregivers' beliefs and attitudes regarding co-prescription of naloxone spray with opioids may help to identify barriers to prescribing and helping tailor the education to better meet the needs of patients and caregivers.

Full description

PRIMARY OBJECTIVE:

I. To determine the proportion of high risk patients who perceive receiving a prescription of intranasal naloxone to be beneficial for them.

SECONDARY OBJECTIVES:

I. To determine the proportion of caregivers who perceive receiving a prescription of intranasal naloxone to be beneficial for the patient.

II. To determine the association between high risk patients' and their caregivers' characteristics (this includes cut-annoyed-guilty-eye [CAGE], screener and opioid assessment for patients with pain [SOAPP], age, gender, ethnicity, education, employment status, presence of caregiver, cancer type, cancer stage, reason for Narcan prescription, health insurance, and setting of Narcan prescription) and their perception that a prescription for intranasal naloxone is beneficial for patients.

EXPLORATORY OBJECTIVE:

I. To conduct an exploratory analysis of high risk patients' and caregivers' attitudes and beliefs regarding prescription of intranasal naloxone spray.

OUTLINE:

Participants complete a survey over 30 minutes.

Enrollment

182 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Patients must have been prescribed intranasal naloxone in the past 1 year
Patients and caregivers must be able to understand, read, write, and speak English
Patients must have no clinical evidence of cognitive impairment, as determined by the palliative care provider (Memorial Delirium Assessment Scale score of >= 7)
Patients must sign an informed consent
Caregivers may sign an informed consent if available during the visit
Caregivers may verbally consent over the phone if not present during the visit
Caregiver must be a friend, significant other or family member
Caregivers must have no evidence of cognitive impairment, as determined based on orientation questions pertaining to the date, day of the week, time, and place

Exclusion criteria

PATIENT: Emotional or psychosocial distress as identified by the patient's palliative care
PATIENT: Participants with Edmonton Symptom Assessment System (ESAS) anxiety score of > 6